Burning Rock Biotech (BNR) has released an update.
Burning Rock Biotech reported a slight revenue increase to RMB128.6 million for Q3 2024, driven by a strong performance in in-hospital and pharma research services, despite a decline in central lab business. The company’s strategic moves include a partnership with MGI Tech and approval for a groundbreaking lung cancer diagnostic, which could bolster its market position. Notably, Burning Rock achieved a significant reduction in operating expenses, leading to a narrowed net loss of RMB35.7 million.
For further insights into BNR stock, check out TipRanks’ Stock Analysis page.